Drug Profile
Budesonide/formoterol - AstraZeneca
Alternative Names: Alenia; Formoterol/budesonide; Symbicort; Symbicort pMDI; Symbicort SMART; Symbicort TurbuhalerLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Biosintetica
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 27 Feb 2023 AstraZeneca initiates enrolment in a phase III trial for Asthma (In adolescents, In children, In the elderly, In adults) in USA(Inhalation)(NCT05755906)
- 27 Feb 2023 Phase-III clinical trials in Asthma (In adolescents, In children, In the elderly, In adults) in Czech Republic (Inhalation)(NCT05755906)
- 20 Dec 2022 AstraZeneca initiates the phase III LITHOS trial in Asthma (In adolescents, In adults, In Children, In the elderly) in Germany (Inhalation) (EudraCT2021-003334-36)